Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice

Journal of Hypertension

Volumn 26, Issue 11, 2008, Pages 2230-2235

  Barrios, Vivencio ^a   Escobar, Carlos ^b   Murga, Nekane ^c   De Pablo, Carmen ^a   Bertomeu, Vicente ^d   Calderón, Alberto ^e   Echarri, Rocio ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^e Primary Care Center Rosa Luxemburgo   (Spain)

Author keywords

Cardiologist setting; Chronic ischemic heart disease; Creatinine; Hypertension; Modification of Diet in Renal Disease; Renal impairment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOLOGIST; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; BLOOD; CARDIOLOGY; CHRONIC KIDNEY FAILURE; HEART MUSCLE ISCHEMIA; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PROFESSIONAL PRACTICE;

AGED; CARDIOLOGY; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROFESSIONAL PRACTICE;

EID: 56049083015     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328311cdee     Document Type: Article

References (32)

1. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16:180-188.
2. Rahman M, Pressel S, Davis BR, Nwachuku C,Wright JT Jr,Whelton PK, et al.Cardiovascular outcomes in high-risk hypertensive patients stratied by baseline glomerular filtration rate. Ann Intern Med 2006; 144:172-180.
3. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratication. Ann Intern Med 2003; 139:137-147.
4. Aronow WS, Ahn C, Mercando AD, Epstein S. Prevalence of coronary artery disease, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufciency and with normal renal function. Am J Cardiol 2000; 86:1142-1143.
5. Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
7. Ruilope LM, Zanchetti A, Julius S, McInnes GT, Segura J, Stolt P, et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007; 25:1473-1479.
8. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
9. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective Benefits of renin-angiotensin system inhibition. Ann Intern Med 2002; 136:604-615.
10. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161:1207-1216.
11. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999; 10:1793-1800.
12. McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis 1997; 29:368-375.
13. Hillis GS, Croal BL, Buchan KG, El-Shafei H, Gibson G, Jeffrey RR, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 2006; 113:1056-1062.
14. Chonchol MB, Aboyans V, Lacroix P, Smits G, Berl T, Laskar M. Long-term outcomes after coronary artery bypass grafting: preoperative kidney function is prognostic. J Thorac Cardiovasc Surg 2007; 134:683-689.
15. Kangasniemi OP, Mahar MA, Rasinaho E, Satomaa A, Tiozzo V, Lepojä rvi M, et al. Impact of estimated glomerular filtration rate on the 15-year outcome after coronary artery bypass surgery. Eur J Cardiothorac Surg 2008; 33:198-202.
16. Khalique O, AronowWS, Ahn C, Mazar M, Schair B, Shao J, et al. Relation of moderate or severe reduction in glomerular filtration rate to number of coronary arteries narrowed >50% in patients undergoing coronary angiography for suspected coronary artery disease. Am J Cardiol 2007; 100:415-416.
17. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
18. Barrios V, Escobar C, Bertomeu V, Murga N, de Pablo C, CalderónA, et al. Risk factor control in the hypertensive patients with chronic ischemic heart disease attended in cardiologic outpatient clinics. The CINHTIA study. Rev Clin Esp 2008; 208: 397-401.
19. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) nal report. Circulation 2002; 106:3143-3421.
21. American Diabetes Association. Clinical Practice Recommendations 2005. Diabetes Care 2005; 28 (Suppl 1):S1-S79.
22. Newsome BB,Warnock DG, McClellanWM, Herzog CA, Kiefe CI, Eggers PW, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008; 168:609-616.
23. Barrios V, Escobar C, Calderón A, Echarri R, González-Pedel V, Ruilope LM, CONTROLRISK Investigators. Cardiovascular risk profile and risk stratication of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens 2007; 21:479-485.
24. Barrios V, Banegas JR, Ruilope LM, Rodicio JL. Evolution of blood pressure control in Spain. J Hypertens 2007; 25:1975-1977.
25. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22:554-572.
26. Tranche S, Lopez I, Mostaza JM, Soler B, Mantilla MT, Taboada M, et al. Control of coronary risk factors in secondary prevention: PRESENAP study. Med Clin 2006; 127:765-769.
27. Saradis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008; 121:332-340.
28. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73-87.
29. Cravedi P, Ruggenenti P, Remuzzi G. Intensied inhibition of renin-angiotensin system: a way to improve renal protection Curr Hypertens Rep 2007; 9:430-436.
30. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
31. Barrios V, Escobar C, Calderón A, Llisterri JL, Echarri R, AlegrfíaE, et al. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J Clin Hypertens (Greenwich) 2007; 9:324-329.
32. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratication. Am J Kidney Dis 2002; 39 (Suppl 2):S1-S266.